Product
IGV-001
Aliases
IGV-001 Cell Immunotherapy
1 clinical trial
1 indication
Indication
GlioblastomaClinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With GlioblastomaStatus: Recruiting, Estimated PCD: 2025-01-01